Document is current
Any future updates will be listed below
-
Authors
Shah, Eric D.
Sharma, Amol
Curren, Nijmeh
Laitman, Adam P.
Staller, Kyle
-
Funding
Funding for this research was provided by:
Salix Pharmaceuticals (Technical editorial support)
Salix Pharmaceuticals (Open access/rapid fee funding)
Salix Pharmaceuticals (Employee salary)
- License Information
-
More Information
Article History
Received: 21 November 2025
Accepted: 13 May 2026
First Online: 12 June 2026
Declarations
:
: Eric D. Shah reports being a consultant for AbbVie, Ardelyx, Cook Group, Laborie Medical Technologies, Mahana Therapeutics, Mylan (Viatris), NeurAxis, Salix Pharmaceuticals, Sanofi, and Takeda Pharmaceutical; holding stock in NeurAxis; and having a patent with the Regent of the University of Michigan. Amol Sharma is a consultant for Atmo Biosciences and has received research support from Vibrant Gastro. Nijmeh Curren and Adam P. Laitman are employees of Salix Pharmaceuticals. Kyle Staller has served as a consultant to Anji Pharmaceuticals, Ardelyx, Gemelli Biotech, Laborie Medical Technologies, Mahana Therapeutics, ReStalsis Health, Salix Pharmaceuticals, and Takeda Pharmaceutical, and has received research support from Ardelyx and ReStalsis Health.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
